Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06447025Phase 2Recruiting

An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia

Role: lead

NCT06681766Phase 1Terminated

A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

Role: lead

NCT05579691Phase 2Completed

A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

Role: lead

NCT05028764Completed

Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers

Role: lead

NCT04519567Phase 1Completed

Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

Role: lead

NCT04176991Phase 1Completed

Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia

Role: lead

NCT04255680Completed

A Study to Assess Variation in Potential Biomarkers in Friedreich Ataxia

Role: lead

All 7 trials loaded